Traws Pharma Q3 2026 net loss narrows 10% to $3.55 million
TRAW•Traws Pharma’s third-quarter 2026 net loss narrowed 10% year over year to $3.55 million, while cash and cash equivalents fell 39% to $2.34 million at September 30. The company also reported clinical and regulatory progress and an agreement allowing up to $50 million in common stock sales, with no shares sold.
1. Quarterly results and cash
Traws Pharma’s third-quarter 2026 net loss narrowed 10% year over year to $3.55 million. Cash and cash equivalents were $2.34 million at September 30, 2026, down 39% from December 31, 2025. An October agreement allows up to $50 million in common stock sales to Roth Principal Investments; no shares have been sold.
2. Drug development updates
Positive final Phase 2a results for ratutrelvir support planned FDA discussions about a registration strategy for patients ineligible for PAXLOVID. Successful tablet bridging and completed toxicology retesting support a planned fourth-quarter 2026 regulatory resubmission for influenza candidate tivoxavir marboxil.




